Philip Clay is Director and principal toxicologist with Chorley Consulting. He is the UK and European registered toxicologist and specializes in product safety assessment with over 30 years of experience in toxicology and safety assessment. He is a BSI committee member on CH/194 (Biological evaluation of medical devices) and Principal Expert for WG6 (Mutagenicity, carcinogenicity and reproductive toxicity).
He established his reputation as a genetic toxicologist working within the agrochemical, chemical, and pharmaceutical industries. He has contributed to many expert panels, helping to shape the testing guidelines and strategies in place today.
More recently, this experience and depth of understanding have been applied to designing safety assessment programs for medical devices and consumer healthcare products for global FMCG businesses. He is presently a member of a Consumer Healthcare Products Association (CHPA) expert group lobbying US FDA regarding the use of in vitro data in the assessment of the biocompatibility of medical devices.